TELA BioNASDAQ: TELA

MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.

TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.52 per share a year ago.

OviTex sales continue to see strong annual growth. However, before being able to conclusively say that OviTex is better than competitors, some head-to-head data is needed. The liquidity position is not great, and dilution seems likely.

TELA Bio, Inc. (NASDAQ:TELA ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Operator Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.80 per share a year ago.

TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MALVERN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023.

TELA Bio, Inc. (NASDAQ:TELA ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Louisa Smith - Gilmartin Group Tony Koblish - President and CEO Roberto Cuca - COO and CFO Conference Call Participants Kyle Rose - Canaccord David Turkaly - JMP Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.